Fortune India 500 2025 edition
Rank#356- Total income
- ₹6,902 Cr
- Profit
- ₹1,414 Cr
Last year #361
Abbott India Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Active Listed - NSE: ABBOTINDIA · BSE: 500488 Public Limited Company pharma Fortune India 500 · #356 Fortune MNC 500 · #52 Nifty 500
Market Cap
₹53,890 Cr
ABBOTINDIA · NSE
Share Price
₹24,815.00
-2.15% today
Revenue
₹6,960 Cr
FY 2025-26 · +8.0% YoY
EBITDA
₹1,892 Cr
Margin 27.2%
Net Profit
₹1,547 Cr
FY 2025-26 · +9.3% YoY
P/E (TTM)
56.6x
P/B 17.5x
ROE
34.5%
ROCE 43.8%
Debt / Equity
0.04
Interest cover 1.4x
About Abbott India Limited
Data last updated:
Abbott India Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Abbott Capital India Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 22 August 1944 and has been in existence for over 82 years.
Abbott India is ranked #356 on the Fortune India 500 (2025) and #52 on the Fortune MNC 500 India (2026). It is part of the Nifty 500 and BSE 500 indices.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24239MH1944PLC007330. Its GSTIN is 27AAACB5170B1Z6 (Maharashtra). The company holds 30 GST registrations, of which 25 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500488 and NSE: ABBOTINDIA.
The company has an authorised share capital of ₹27.5 Cr and a paid-up capital of ₹21.25 Cr. It was formerly known as Boots Pure Drug Company (India) Private Limited. It is led by directors including Kartik Rajendran (Managing Director) and Munir Shaikh.
Its last annual general meeting (AGM) was held on 13 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Unit No. 3 Corporate Park Sion Trombay Road Chembur, Mumbai, Maharashtra, India – 400071.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹6,960.49 Cr, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹1,546.8 Cr (net margin 22.2%) and EBITDA of ₹1,892.08 Cr (EBITDA margin 27.2%). The net worth stands at ₹4,774.19 Cr (up 12.8% YoY). Total assets are valued at ₹5,063.69 Cr (up 11.3% YoY).
The company has about 3,924 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Cremaffin and Abbott. Court records list 498 cases involving the company, including 393 filed by the company and 105 filed against it; 176 cases are pending. The company has 8 deals on record (7 market trades, 1 acquisition); the latest was in April 2018. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Ipca Laboratories Limited with revenue of ₹9,032.39 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 2,119 overdue payments to 296 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website abbott.co.in.
Company details
CIN L24239MH1944PLC007330
Registration Number 007330
Incorporation Date 22 August 1944
ROC Mumbai
Listing Status Listed - Listed on NSE (ABBOTINDIA); Listed on BSE (500488)
Company Status Active
Date of Last AGM 13 August 2026
Date of Balance Sheet 31 March 2026
Parent Company Abbott Capital India Limited
Compliance Status Active Compliant
CIN history
Abbott India has one previous CIN (Corporate Identification Number): L24239MH1949PLC007330. The current CIN is L24239MH1944PLC007330, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239MH1944PLC007330 | Current |
| L24239MH1949PLC007330 | Previous |
Recognitions & Rankings of Abbott India
Fortune MNC 500 India 2026 edition
Rank#52- Total income
- ₹16,811 Cr
- Profit
- ₹2,555 Cr
Last year #54
Stock market indices
Nifty 500 BSE 500
Contact details
Abbott India Limited's registered office is in Mumbai, Maharashtra. Its website is abbott.co.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressUnit No. 3 Corporate Park Sion Trombay Road Chembur, Mumbai, Maharashtra, India – 400071
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Abbott India Limited, buy the company report.
Comprehensive company report
Abbott India Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Abbott India operates two associated brands: Cremaffin and Abbott. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Developer of medical devices, generic pharmaceuticals, and nutrition products | abbott.com | |
| Provision of constipation relief products and services is handled by Cremaffin. | cremaffin.com |
Business activity
The main business activity of Abbott India is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Abbott India Limited, buy the company report.
Financials of Abbott India Limited
FY 2025-26 filings availableAbbott India Limited reported revenue of ₹6,960.49 Cr (up 8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹6,960 Cr
+8.0% YoY
EBITDA
₹1,892 Cr
+11.7% YoY
Profit After Tax
₹1,547 Cr
+9.3% YoY
Net Worth
₹4,774 Cr
+12.8% YoY
Total Assets
₹5,064 Cr
+11.3% YoY
Total Debt
₹172 Cr
-12.5% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 6,960 | 6,446 | 5,875 | 5,379 | 4,919 | 4,310 | 4,093 |
| Revenue growth | +8.0% | +9.7% | +9.2% | +9.4% | +14.1% | +5.3% | - |
| EBITDA | 1,892 | 1,695 | 1,453 | 1,206 | 1,088 | 921 | 756 |
| EBITDA margin | +27.2% | +26.3% | +24.7% | +22.4% | +22.1% | +21.4% | +18.5% |
| Profit before tax | 2,079 | 1,887 | 1,618 | 1,274 | 1,080 | 926 | 803 |
| Net profit | 1,547 | 1,415 | 1,201 | 950 | 799 | 691 | 593 |
| Net profit margin | +22.2% | +22.0% | +20.4% | +17.7% | +16.2% | +16.0% | +14.5% |
| EPS (₹) | 730.36 | 665.62 | 565.28 | 446.78 | 375.86 | 325.03 | 279.03 |
| Balance sheet | |||||||
| Total assets | 5,064 | 4,549 | 3,897 | 3,395 | 3,064 | 2,844 | 2,691 |
| Net worth | 4,774 | 4,233 | 3,699 | 3,189 | 2,820 | 2,602 | 2,432 |
| Total debt | 172 | 197 | 83.23 | 113 | 152 | 153 | 175 |
| Cash & bank | 2,255 | 1,626 | 2,134 | 1,937 | 2,749 | 2,409 | 2,197 |
| Net working capital | 2,332 | 3,395 | 1,950 | 1,865 | 2,693 | 2,491 | 2,349 |
| Cash flow | |||||||
| Cash from operations | 1,319 | 1,012 | 1,213 | 893 | 948 | 727 | 626 |
| Cash from investing | (371) | 182 | (416) | (148) | (396) | (71.82) | (401) |
| Cash from financing | (1,066) | (925) | (745) | (639) | (637) | (582) | (217) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,814 | 1,710 | 1,724 | 1,757 | 1,738 | 1,605 | 1,614 | 1,633 |
| Revenue growth (YoY) | +4.3% | +6.5% | +6.8% | +7.6% | +11.6% | - | - | - |
| Other income | 75.37 | 75.59 | 69.76 | 69.95 | 72.84 | 76.02 | 71.75 | 60.48 |
| Total expenses | 1,291 | 1,229 | 1,261 | 1,255 | 1,293 | 1,176 | 1,178 | 1,194 |
| EBITDA | 522 | 481 | 463 | 502 | 446 | 429 | 436 | 439 |
| EBITDA margin | +28.8% | +28.1% | +26.9% | +28.6% | +25.6% | +26.7% | +27.0% | +26.9% |
| Depreciation | 19.75 | 19.07 | 18.77 | 18.64 | 19.48 | 17.93 | 17.99 | 17.51 |
| Interest | 5.91 | 6.14 | 5.48 | 7.55 | 5.82 | 3.92 | 2.26 | 2.50 |
| Profit before tax | 572 | 531 | 509 | 546 | 493 | 483 | 488 | 479 |
| Tax | 144 | 136 | 133 | 131 | 127 | 116 | 127 | 121 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,814 | 1,710 | 1,724 | 1,757 | 1,738 | 1,605 | 1,614 | 1,633 |
| Revenue growth (YoY) | +4.3% | +6.5% | +6.8% | +7.6% | +11.6% | - | - | - |
| Other income | 75.37 | 75.59 | 69.76 | 69.95 | 72.84 | 76.02 | 71.75 | 60.48 |
| Total expenses | 1,291 | 1,229 | 1,261 | 1,255 | 1,293 | 1,176 | 1,178 | 1,194 |
| EBITDA | 522 | 481 | 463 | 502 | 446 | 429 | 436 | 439 |
| EBITDA margin | +28.8% | +28.1% | +26.9% | +28.6% | +25.6% | +26.7% | +27.0% | +26.9% |
| Depreciation | 19.75 | 19.07 | 18.77 | 18.64 | 19.48 | 17.93 | 17.99 | 17.51 |
| Interest | 5.91 | 6.14 | 5.48 | 7.55 | 5.82 | 3.92 | 2.26 | 2.50 |
| Profit before tax | 572 | 531 | 509 | 546 | 493 | 483 | 488 | 479 |
| Tax | 144 | 136 | 133 | 131 | 127 | 116 | 127 | 121 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 6,960 | 6,446 | 5,875 | 5,379 | 4,919 | 4,310 | 4,093 |
| Revenue growth | +8.0% | +9.7% | +9.2% | +9.4% | +14.1% | +5.3% | - |
| Other income | 288 | 276 | 248 | 154 | 77.21 | 80.90 | 114 |
| Total expenses | 5,068 | 4,751 | 4,422 | 4,173 | 3,832 | 3,389 | 3,337 |
| Employee cost | 669 | 588 | 577 | 564 | 579 | 493 | 476 |
| EBITDA | 1,892 | 1,695 | 1,453 | 1,206 | 1,088 | 921 | 756 |
| EBITDA margin | +27.2% | +26.3% | +24.7% | +22.4% | +22.1% | +21.4% | +18.5% |
| Depreciation | 75.96 | 71.80 | 71.17 | 69.97 | 66.10 | 58.13 | 59.61 |
| Interest | 24.99 | 11.43 | 12.45 | 15.99 | 19.10 | 18.28 | 8.53 |
| Profit before tax | 2,079 | 1,887 | 1,618 | 1,274 | 1,080 | 926 | 803 |
| Tax | 527 | 473 | 417 | 324 | 281 | 235 | 210 |
| Net profit | 1,547 | 1,415 | 1,201 | 950 | 799 | 691 | 593 |
| Net profit margin | +22.2% | +22.0% | +20.4% | +17.7% | +16.2% | +16.0% | +14.5% |
| EPS (₹) | 730.36 | 665.62 | 565.28 | 446.78 | 375.86 | 325.03 | 279.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 21.25 | 21.25 | 21.25 | 21.25 | 21.25 | 21.25 | 21.25 |
| Reserves & surplus | 4,753 | 4,212 | 3,678 | 3,167 | 2,799 | 2,581 | 2,410 |
| Shareholders' funds (net worth) | 4,774 | 4,233 | 3,699 | 3,189 | 2,820 | 2,602 | 2,432 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 172 | 197 | 83.23 | 113 | 152 | 153 | 175 |
| Total debt | 172 | 197 | 83.23 | 113 | 152 | 153 | 175 |
| Total liabilities | 5,064 | 4,549 | 3,897 | 3,395 | 3,064 | 2,844 | 2,691 |
| Assets | |||||||
| Gross block | 567 | 553 | 424 | 367 | 382 | 341 | 345 |
| Net block | 331 | 336 | 225 | 237 | 271 | 251 | 270 |
| Capital work in progress | 5.51 | 18.08 | 10.11 | 3.66 | 0.66 | 0.66 | 1.64 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 947 | 882 | 620 | 649 | 688 | 718 | 527 |
| Sundry debtors | 362 | 380 | 319 | 317 | 288 | 250 | 318 |
| Cash & bank balances | 2,255 | 1,626 | 2,134 | 1,937 | 2,749 | 2,409 | 2,197 |
| Loans & advances | 207 | 1,875 | 173 | 122 | 128 | 111 | 162 |
| Total current assets | 3,771 | 4,763 | 3,246 | 3,025 | 3,853 | 3,487 | 3,205 |
| Total current liabilities | 1,438 | 1,368 | 1,296 | 1,160 | 1,160 | 996 | 855 |
| Net working capital | 2,332 | 3,395 | 1,950 | 1,865 | 2,693 | 2,491 | 2,349 |
| Total assets | 5,064 | 4,549 | 3,897 | 3,395 | 3,064 | 2,844 | 2,691 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 561 | 292 | 240 | 133 | 218 | 145 | 137 |
| Net cash from operating activities | 1,319 | 1,012 | 1,213 | 893 | 948 | 727 | 626 |
| Net cash from investing activities | (371) | 182 | (416) | (148) | (396) | (71.82) | (401) |
| Net cash from financing activities | (1,066) | (925) | (745) | (639) | (637) | (582) | (217) |
| Net change in cash | (118) | 269 | 52.07 | 107 | (85.56) | 73.13 | 8.13 |
| Closing cash | 2,255 | 1,626 | 2,134 | 1,937 | 2,749 | 2,409 | 2,197 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +8.0% | +9.7% | +9.2% | +9.4% | +14.1% | +5.3% | - |
| EBITDA growth | +11.7% | +16.6% | +20.5% | +10.8% | +18.0% | +21.8% | - |
| PBT growth | +10.2% | +16.6% | +27.0% | +18.0% | +16.6% | +15.4% | +14.9% |
| Net income growth | +9.3% | +17.8% | +26.5% | +18.9% | +15.6% | +16.4% | - |
| Revenue CAGR (3Y) | +9.0% | +9.4% | +10.9% | +9.5% | +10.2% | +9.3% | +12.1% |
| EBITDA CAGR (3Y) | +16.2% | +15.9% | +16.4% | +16.8% | +21.6% | +20.7% | +23.9% |
| Profitability & leverage | |||||||
| Net income margin | +22.3% | +21.9% | +20.5% | +17.7% | +16.2% | +16.0% | +14.5% |
| Return on capital employed | +43.8% | +45.0% | +44.7% | +39.9% | +37.2% | +34.1% | +34.0% |
| Return on net worth | +34.5% | +35.7% | +34.9% | +31.6% | +29.5% | +27.4% | +26.7% |
| Debt / equity | 0.04 | 0.04 | 0.03 | 0.04 | 0.06 | 0.07 | 0.04 |
| Long-term debt / equity | 0.03 | 0.02 | 0.02 | 0.03 | 0.04 | 0.05 | 0.03 |
| Interest cover | 1.38 | 0.70 | 0.90 | 1.41 | 1.87 | 2.12 | 1.22 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 12.43 | 13.19 | 14.85 | 14.37 | 13.62 | 12.58 | 16.08 |
| Inventory turnover | 7.61 | 8.59 | 9.26 | 8.05 | 7.00 | 6.93 | 7.22 |
| Debtors turnover | 18.76 | 18.43 | 18.47 | 17.78 | 18.27 | 15.17 | 13.78 |
| EPS (₹) | 730.36 | 665.62 | 565.28 | 446.78 | 375.86 | 325.03 | 279.03 |
| Dividend per share (₹) | 656.00 | 475.00 | 410.00 | 325.00 | 275.00 | 275.00 | 250.00 |
| Book value per share (₹) | 2,246.68 | 1,992.07 | 1,740.65 | 1,500.49 | 1,326.96 | 1,224.55 | 1,144.33 |
To see the full year-wise statements and ratios of Abbott India Limited, buy the company report.
Board of directors and KMP of Abbott India Limited
Abbott India Limited currently reports 10 directors and 1 key managerial person. 31 former directors have served the organization.
Current Directors and KMP
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Munir Shaikh | Director | 02 Mar 2001 | 25 Years 7 Months | Current |
| Neeraj Jain Also directs: Popular Vehicles and Services Limited, Sheela Foam Limited, Aster DM Quality Care Limited and 5 more | Director | 25 Apr 2026 | 0 Years 5 Months | Current |
| Alison Elizabeth Davies | Director | 13 Jun 2024 | 2 Years 4 Months | Current |
| Shalini Kalsi Kamath Also directs: Bosch Home Comfort India Limited, Expleo Solutions Limited, Healthium Medtech Limited and 3 more | Director | 29 Oct 2019 | 6 Years 11 Months | Current |
| Maithilee Kaizad Mistry | Cfo | 06 May 2025 | 1 Years 5 Months | Current |
| Sudarshan Kailash Chandra Jain | Director | 01 Apr 2019 | 7 Years 6 Months | Current |
Showing 6 of 11 current directors and KMP. View all directors and KMP
Peer comparison
Abbott India Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ipca Laboratories Limited | ₹9,032.39 Cr (FY 2025) | 15.0% | Mumbai, Maharashtra, India | |||
| Abbott Healthcare Private Limited | ₹8,811.32 Cr (FY 2025) | 3.0% | Mumbai, Maharashtra, India | |||
| Emcure Pharmaceuticals Limited | ₹7,963.26 Cr (FY 2025) | 19.0% | Pune, Maharashtra, India | |||
| Abbott India Limitedthis company | ₹6,960.49 Cr (FY 2026) | ₹1,546.8 Cr | 22.2% | 8.0% | 3,924 | Mumbai, Maharashtra, India |
| MSN Laboratories Private Limited | ₹6,761.18 Cr (FY 2024) | 27.0% | Hyderabad, Telangana, India | |||
| Micro Labs Limited | ₹6,499.64 Cr (FY 2025) | -2.0% | Bengaluru, Karnataka, India | |||
| Aristo Pharmaceuticals Private Limited | ₹5,363.3 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Usv Private Limited | ₹5,202.13 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Eugia Pharma Specialities Limited | ₹4,828.71 Cr (FY 2025) | 12.0% | Hyderabad, Telangana, India | |||
| Natco Pharma Limited | ₹4,784 Cr (FY 2025) | 16.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Abbott India Limited, buy the company report.
Auditor
Abbott India Limited is audited by Walker Chandiok & Co LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2025 | 001076N/N500013 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 75.00%, foreign institutional investors hold 0.40%, domestic institutional investors hold 8.80% and retail and other public shareholders hold 15.80%.
Sep 2026
QUARTER
75.00% Promoters
8.80% DII (Domestic Institutional)
0.40% FII (Foreign Institutional)
15.80% Retail & Others
Promoter holding - history
Now 75.00% · Sep 2026High 75.00% · Dec 2025Low 75.00% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% |
| Public | 25.00% | 25.00% | 25.00% | 25.00% |
Deals & funding
Abbott India Limited has 8 deals on record (7 market trades, 1 acquisition); the latest was in April 2018.
Total deals
8
Market trades
7
Acquisition
1
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2018 | Acquisition | Undisclosed | Buyer: Corona Remedies Limited Seller: Abbott India Limited |
| May 2011 | Market trade | ₹32.21 Cr | Buyer: Reliance Mutual Fund (Scheme : Reliance Capital Trustee Co. Seller: Abbott Capital India Limited |
| Sep 2009 | Market trade | ₹11.54 Cr | Buyer: Arion Commercial Pvt Ltd |
| Jun 2007 | Market trade | ₹30.58 Cr | Buyer: Reliance Capital Trustee Co Ltd A C Reliance Long Term Equit Seller: Hdfc Trustee Co Ltd A C Hdfc Long Term Equity Fund |
| Jun 2006 | Market trade | ₹12.61 Cr | Buyer: Hfdc Long Term Equity Fun Seller: an individual |
To see the full deal history of Abbott India Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Abbott India Limited has 498 court cases on record: 393 filed by Abbott India, 105 filed against it. 176 cases are pending and 322 are disposed.
Total cases
498
Filed by the company
393
Filed against the company
105
Pending
176
Disposed
322
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 409 | 49 | 148 |
| High courts | 83 | 51 | 23 |
| Supreme Court | 5 | 4 | 4 |
| NCLAT | 1 | 1 | 1 |
Cases on record (5 of 498)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, New Delhi, Delhi | Cheque dishonour complaint | Filed by the company against Shree Maruti Nandan Pharmaceuticals Pvt Ltd | Pending |
| District court, Ernakulam, Kerala | Criminal case | Filed by the company against The Proprietor, Unity Pharma | Pending |
| District court, Patna, Bihar | Court case (Cr. Case Complaint (P)) | Filed by the company against M/S Bhawani Industries Through Its Proprietor Namely Vijay Kumar | Pending |
| High Court, TELANGANA | Court case (CCCA) | Filed against the company by M/S.Chemsol Labs Private Limited | Pending |
| District court, North Twenty Four Parganas, West Bengal | Civil suit | Filed against the company by Agarpara Jute Mills Ltd,Jitendra Nath Choubey | Pending |
To see the full case history of Abbott India Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Abbott India Limited has 14 MSME Form 1 returns on record between 2019 and 2024, listing 2,119 overdue payments to 296 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 296)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Airmark Inc | |||
| an individual supplier | |||
| Sunshine Organics Pvt Ltd | |||
| Asian Supply Chain Solutions Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Abbott India Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Abbott India Limited has a workforce of 3,924 employees on its EPFO records as of Sep 24, 2025, across 7 active EPFO establishments.
Employee count
3,924
Active EPFO establishments
7
Employee growth
-3.47%
GST
Abbott India has 30 GST registrations: 25 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
30
Active
25
Cancelled / inactive
5
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACB5170B1Z6 | Maharashtra | Active | 01 Jul 2017 |
| 27AAACB5170B2Z5 | Maharashtra | Active | 12 Aug 2017 |
| 02AAACB5170B1ZI | Himachal Pradesh | Active | 01 Jul 2017 |
| 03AAACB5170B1ZG | Punjab | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Abbott India Limited, buy the company report.
Recent activity
Abbott India Limited has 40 board changes on record since 2001: 11 appointments and 29 cessations. The latest: Neeraj Jain was appointed as Director on 25 Apr 2026.
AGM
Abbott India Limited last Annual general meeting of members was held on 13 Aug 2026 as per latest MCA records.
Appointed
Neeraj Jain was appointed as Director.
Appointed
James Russell Wenner was appointed as Director.
Filing
Abbott India Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Appointed
Vivek Mohan was appointed as Director.
Appointed
Darshan Pravin Gada was appointed as Director.
Appointed
Kartik Rajendran was appointed as Managing Director.
Appointed
Maithilee Kaizad Mistry was appointed as CFO.
Ceased
Sridhar Venkateswaran Kadangode ceased to be Additional Director.
Appointed
Alison Elizabeth Davies was appointed as Director.
Ceased
Swati Rohan Dalal ceased to be Additional Director.
Ceased
Mahadeo Purushottam Karnik ceased to be Additional Director.
31 earlier events are in the company report.
News
Frequently asked questions
Abbott India is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 22 August 1944 (82+ years old) and is registered under CIN L24239MH1944PLC007330. Listed on BSE: 500488 and NSE: ABBOTINDIA.
Abbott India reported revenue of ₹6,960.49 Cr for FY 2025-26 (up 8% YoY) based on standalone financials.
Abbott India has 11 current directors and KMP:
- Kartik Rajendran - Managing Director
- Munir Shaikh - Director
- Neeraj Jain - Director
- Alison Elizabeth Davies - Director
- Shalini Kalsi Kamath - Director
- Sudarshan Kailash Chandra Jain - Director
- Kaiyomarz Minoo Marfatia - Director
- Darshan Pravin Gada - Director
- Vivek Mohan - Director
- James Russell Wenner - Director
- Maithilee Kaizad Mistry - Cfo
The latest financial statements of Abbott India on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 13 August 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Abbott India is 27AAACB5170B1Z6, registered in Maharashtra. The company has 30 GST registrations in all, of which 25 are active and 5 are cancelled or inactive. Other active GSTINs include 27AAACB5170B2Z5 (Maharashtra), 02AAACB5170B1ZI (Himachal Pradesh), 03AAACB5170B1ZG (Punjab).
The CIN (Corporate Identification Number) of Abbott India is L24239MH1944PLC007330. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Abbott India is a listed company as per MCA records. Its shares are listed on both BSE (code: 500488) and NSE (symbol: ABBOTINDIA).
Abbott India has 498 court cases on record: 393 filed by the company and 105 filed against it. 176 are pending. Most are in the district courts.
Abbott India was incorporated on 22 August 1944, making it 82+ years old. It is registered with the Registrar of Companies, Mumbai.
Abbott India has 8 deals on record (7 market trades, 1 acquisition); the latest was in April 2018.
The peers of Abbott India by revenue are Ipca Laboratories Limited, Abbott Healthcare Private Limited, Emcure Pharmaceuticals Limited, MSN Laboratories Private Limited, Micro Labs Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Neeraj Jain was appointed as Director on 25 Apr 2026. James Russell Wenner was appointed as Director on 23 Apr 2026. Vivek Mohan was appointed as Director on 01 Jan 2026. Abbott India has 40 board changes on record in total.